» Articles » PMID: 35955729

Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Aug 12
PMID 35955729
Authors
Affiliations
Soon will be listed here.
Abstract

Programmed Cell Death 1 Ligand 1 (PD-L1, CD274, B7-H1) is a transmembrane protein which is strongly involved in immune modulation, serving as checkpoint regulator. Interaction with its receptor, Programmed Cell Death Protein 1 (PD-1), induces an immune-suppressive signal, which modulates the activity of T cells and other effector cells. This mediates peripheral tolerance and contributes to tumor immune escape. PD-L1 became famous due to its deployment in cancer therapy, where blockage of PD-L1 with the help of therapeutic antagonistic antibodies achieved impressive clinical responses by reactivating effector cell functions against tumor cells. Therefore, in the past, the focus has been placed on PD-L1 expression and its function in various malignant cells, whereas its role in healthy tissue and diseases apart from cancer remained largely neglected. In this review, we summarize the function of PD-L1 in non-cancerous cells, outlining its discovery and origin, as well as its involvement in different cellular and immune-related processes. We provide an overview of transcriptional and translational regulation, and expression patterns of PD-L1 in different cells and organs, and illuminate the involvement of PD-L1 in different autoimmune diseases as well as in the context of transplantation and pregnancy.

Citing Articles

Exploring the landscape of current in vitro and in vivo models and their relevance for targeted radionuclide theranostics.

Bokhout L, Campeiro J, Dalm S Eur J Nucl Med Mol Imaging. 2025; .

PMID: 40016527 DOI: 10.1007/s00259-025-07123-3.


Avelumab mediates antibody-dependent cellular cytotoxicity against monocyte-derived dendritic cells through natural killer cells.

Sauerer T, Bremm F, Beenen A, Heger L, Dudziak D, Bosch N MedComm (2020). 2025; 6(3):e70111.

PMID: 39974665 PMC: 11835948. DOI: 10.1002/mco2.70111.


Dual-release hydrocortisone treatment improves serum and peripheral blood mononuclear cell inflammatory and immune profiles in patients with autoimmune primary adrenal insufficiency.

Tomasello L, Coppola A, Pizzolanti G, Giordano C, Arnaldi G, Guarnotta V Front Immunol. 2025; 16:1489254.

PMID: 39917303 PMC: 11798947. DOI: 10.3389/fimmu.2025.1489254.


GDF15/MIC-1: a stress-induced immunosuppressive factor which promotes the aging process.

Salminen A Biogerontology. 2024; 26(1):19.

PMID: 39643709 PMC: 11624233. DOI: 10.1007/s10522-024-10164-0.


The role of inhibitory immune checkpoint receptors in the pathogenesis of Alzheimer's disease.

Salminen A J Mol Med (Berl). 2024; 103(1):1-19.

PMID: 39601807 PMC: 11739239. DOI: 10.1007/s00109-024-02504-x.


References
1.
Li S, Liao W, Chen M, Shan S, Song Y, Zhang S . Expression of programmed death-1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis. Inflammation. 2013; 37(1):116-21. DOI: 10.1007/s10753-013-9718-8. View

2.
Tamura H, Dong H, Zhu G, Sica G, Flies D, Tamada K . B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood. 2001; 97(6):1809-16. DOI: 10.1182/blood.v97.6.1809. View

3.
Marzec M, Zhang Q, Goradia A, Raghunath P, Liu X, Paessler M . Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A. 2008; 105(52):20852-7. PMC: 2634900. DOI: 10.1073/pnas.0810958105. View

4.
Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

5.
Yang Y, Li C, Chan L, Wei Y, Hsu J, Xia W . Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res. 2018; 28(8):862-864. PMC: 6082826. DOI: 10.1038/s41422-018-0060-4. View